|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | ev3 Inc. (NASDAQ:EVVV), a manufacturer focused on endovascular technologies for the minimally invasive treatment of vascular disorders. |
|---|---|
| Transferring Party | FoxHollow Technologies, Inc. (NASDAQ:FOXH), a developer of minimally invasive devices for the treatment of peripheral artery disease (PAD). |
| Sector | Medical Devices |
| Date | July 23, 2007 |
| Analysis Creates a global leadership position in the endovascular device market and offers significant revenue synergies and cost savings. The combined product portfolio will include an extensive line of products to treat vascular disease, including atherectomy and thrombectomy, PTA balloons, stents, embolic protection devices, infusion catheters/wires, embolic coils and liquid embolics. The combined sales force of 240 reps (EVVV has 80, FOXH has 160) will be one of the largest in the endovascular space at nearly twice the size of other players like JNJ, BSX, ABT, and MDT. The major call point are-interventional radiologists. Deal value - $780m, on sales of $198.1m (3.9x) and EBITDA of $24.4 (32.5x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |